What’s Prosetin? If you’ve been following Project ALS, you have probably heard us mention PHB, our working name for The Core’s first drug candidate-in-development. Now,

Project ALS is thrilled to welcome Dr. Ai Yamamoto to the Research Advisory Board and recognizes her leadership as she is joining our decision-making body.

Columbia University and Project ALS today announced the Project ALS Therapeutics Core at Columbia (THE CORE), a 3-year, $6.3M initiative toward the first meaningful therapies

Q&A with Project ALS Researcher Dr. Sebastian Thams, Karolinska Institute, on His Recent Discovery, Published in Molecular Therapy Can you describe your discovery that was